Lerisetron

Lerisetron
Clinical data
Other names	F-0930-RS
ATC code	None;
Identifiers
	IUPAC name 1-Benzyl-2-piperazin-1-yl-1H-benzimidazole;
CAS Number	143257-98-1 ;
PubChem CID	65997;
ChemSpider	59389 ;
UNII	Q36R82SXRG;
ChEMBL	ChEMBL56900 ;
CompTox Dashboard (EPA)	DTXSID90162368 ;
Chemical and physical data
Formula	C18H20N4
Molar mass	292.378 g/mol g·mol−1
	InChI InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2 ; Key:PWWDCRQZITYKDV-UHFFFAOYSA-N ;
(what is this?) (verify)

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT₃ receptor.[1] It is a potent antiemetic[2][3] and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]

References

Orjales, A; Mosquera, R; Labeaga, L; Rodes, R (14 February 1997). "New 2-Piperazinylbenzimidazole Derivatives as 5-HT₃ Antagonists. Synthesis and Pharmacological Evaluation". Journal of Medicinal Chemistry. 40 (4): 586–93. doi:10.1021/jm960442e. PMID 9046349.
Gomez-de-Segura, IA; Grande, AG; De Miguel, E (1998). "Antiemetic Effects of Lerisetron in Radiation-Induced Emesis in the Dog". Acta Oncologica. 37 (7–8): 759–63. PMID 10050999.
Cooper, M; Sologuren, A; Valiente, R; Smith, J (2002). "Effects of Lerisetron, a New 5-HT₃ Receptor Antagonist, on Ipecacuanha-Induced Emesis in Healthy Volunteers". Arzneimittel-Forschung. 52 (9): 689–94. doi:10.1055/s-0031-1299952. PMID 12404884.
Huckle, R (July 2003). "Lerisetron. FAES". Current Opinion in Investigational Drugs. 4 (7): 874–7. PMID 14619411.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.